Abstract: Embodiments of the present disclosure provide a solution for deploying a service. A method includes: receiving a deployment request for deploying a service in a content delivery network (CDN) network, the deployment request at least indicating a plurality of clusters of CDN nodes where the service is to be deployed; receiving a base deployment configuration for the plurality of clusters of CDN nodes; receiving at least one deployment configuration overlay specific to at least one of the plurality of clusters of CDN nodes, a deployment configuration overlay specific to a cluster of CDN nodes indicating a delta configuration on top of the base deployment configuration that is applied to the cluster of CDN nodes; and deploying the service in the CDN network based on the base deployment configuration and the at least one deployment configuration overlay.

Abstract: The present invention relates to a X-form crystal of 17-cyclopropylmethyl-3,14?-dihydroxy-4,5?-epoxy-6?-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride and the manufacturing method thereof, wherein the X-form crystal of the compound has characteristic diffraction peaks at positions of 2? of 13.6°(±0.2°), 17.2°(±0.2°), 19.1°(±0.2°), 23.2°(±0.2°), and 23.8°(±0.2°) in a powder X-ray diffraction pattern thereof. The present invention also relates to a pharmaceutical composition comprising the above-mentioned X-form crystal of morphinan derivative hydrochloride.

Abstract: This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.

Abstract: This invention relates to piperazinedione compounds shown in the specification. These compounds are tyrosine kinase inhibitors and can be used to treat cancer.